MPO and ganglioneuroma: A pivotal pre-clinical study found that avacopan blocked human C5aR in mice with MPO antibody-induced GN, significantly reducing the number of glomerular crescents from approximately 30.4% to 3.3% and reducing levels of hematuria (P < 0.001), proteinuria (P < 0.01) and leukocyturia (P < 0.001) [37].